LIGAND PHARMACEUTICALS INC LGND revenue by segment, product and geography
In its fiscal year ending 2025-12-31, LIGAND PHARMACEUTICALS INC reported revenue across 1 business segments; the largest, Development And Licensing Of Biopharmaceutical Assets, was $268M, 100.0% of the filed sum (+60.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Development And Licensing Of Biopharmaceutical Assets$268M100.0%+60.4% yoy
Members sum to the consolidated $268M for this period.
- Development And Licensing Of Biopharmaceutical Assets$124Mshare n/a-3186.6% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Royalty$161Mshare n/a+48.0% yoy
- Intangible Royalty Assets$133Mshare n/a+39.0% yoy
- Contract Revenue$66.9Mshare n/a+143.4% yoy
- Contract Revenue And Income$66.9Mshare n/a+143.4% yoy
- Income From Divestiture Transactions$53.1Mshare n/ano prior
- Material Sales Captisol Core$40.2Mshare n/a+30.2% yoy
- Material Sales Captisol$40.2Mshare n/a+30.2% yoy
- Royalty Kyprolis$35.5Mshare n/a-7.4% yoy
- +13 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Development And Licensing Of Biopharmaceutical Assets$51.7M100.0%+14.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.